Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 28;67(11):2916–2922. doi: 10.1002/art.39265

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Change from baseline in subregional cartilage thickness at 12 months of followup, according to A, subregions of the cartilage and B, ordered values (OVs) of the magnitude of change in cartilage thickness (ranging from OV1, representing greatest cartilage loss, to OV16, representing greatest cartilage thickening). Significant treatment effects (unadjusted P < 0.05) were detected in 4 of 16 subregions and in 10 of 16 OVs. Bars show the mean and 95% confidence interval (95% CI). Symbols indicate individual change values that differed significantly between the 100 μg sprifermin–treated and placebo‐treated patients. MT = medial tibia; cMF = central part of the medial weight‐bearing femur; LT = lateral tibia; cLF = central part of the lateral weight‐bearing femur.